Recurrent second-trimester intrauterine fetal death due to undiagnosed atrioventricular block: A case report by Abbas, Ahmed M. et al.
                                                   Proceedings in Obstetrics and Gynecology, 2017;7(2):7 
Please cite this paper as: Abbas AM, Ali SEA, Michael A. Recurrent second-trimester intrauterine fetal death due to 
undiagnosed atrioventricular block: A case report. Proc Obstet Gynecol. 2017;7(2): Article 7 [ 7 p.]. Available from: 
http://ir.uiowa.edu/pog/  Free full text article. 
Corresponding author: Ahmed M. Abbas, MD, Woman's Health Hospital, Assiut University, Assiut, Egypt. Business 
telephone number: +20882414698. Cellular phone number: +2 01003385183. Postal code: 71111. email: 
bmr90@hotmail.com    
Financial Disclosure: The authors report no conflict of interest. 
Copyright: © 2017 Abbas et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited. 
1 
 
Recurrent second-trimester intrauterine fetal death due to 
undiagnosed atrioventricular block: A case report 
Ahmed M. Abbas, MD,1 Sief El-Eslam A. Ali, MSc,1 Armia Michael, MBBCh2 
Keywords: Atrioventricular block, hydrops fetalis, intrauterine fetal death, heart failure 
Abstract 
Fetal cardiac abnormalities are one of the 
common causes of non-immune fetal hydrops. 
Early diagnosis and treatment may prevent the 
late consequences that can occur as heart 
failure and intrauterine fetal death. Herein we 
report the case of a 32-year-old patient with a 
history of recurrent second trimester intrauterine 
fetal death. She presented with fetal hydrops at 
23 weeks. A detailed echocardiography revealed 
that the fetus had a third degree atrioventricular 
block and advanced hydropic changes due to 
heart failure. Corticosteroid therapy was started 
but the fetus died in utero after 2 weeks. 
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Introduction  
Hydrops fetalis is defined as abnormal 
fluid accumulation in fetal extravascular 
compartments and body cavities leading 
to edema, ascites, pleural and 
pericardial effusions. It is classified into 
2 groups; immune and non-immune 
hydrops fetalis, with the latter 
representing more than 80% of the 
described causes of hydrops fetalis.1 
Perinatal mortality in hydrops fetalis is 
high unless the original cause is 
recognized and treated properly either 
intrauterine or extrauterine.2 
The most common cause of non-
immune hydrops (NIH) is fetal cardiac 
anomalies.3 Fetal bradyarrhythmia is 
one of the documented causes of NIH.4 
It is a rare but serious disease that leads 
to fetal heart failure without appropriate 
management. An improvement in fetal 
echocardiographic equipment (M-mode 
echocardiogram and Doppler 5) has 
enabled accurate intrauterine 
identification of such arrhythmia. 
Herein, we report the first case of 
recurrent intrauterine fetal death (IUFD) 
in the second trimester pregnant female 
due to heart failure secondary to fetal 
atrioventricular block. 
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Case presentation 
At 23 weeks of gestation, a 32-year-old 
female patient G5P4 (with no living 
children) was referred to our tertiary 
health care center because of hydrops 
fetalis. Her initial investigations revealed 
negative TORSCH screening tests, 
negative Coomb's test and her blood 
group was AB positive Rh factor. 
Ultrasound evaluation performed at the 
fetal medicine unit revealed bi-parietal 
diameter and femur length of 23 weeks. 
Abdominal circumference measured 35 
weeks due to marked fetal ascites 
(Figure 1). 
 
Figure 1: Ultrasound showing marked fetal ascites 
Detailed echocardiography performed 
by a level III sonographer revealed fetal 
cardiomegaly, bradyarrhythmia, 
ventricular contraction independent of 
atrium contraction (3rd degree heart 
block) (video), and lastly, hypertrophy 
and dilatation of all heart champers. A 
non-stress test confirmed the fetal 
bradycardia, which revealed a heart rate 
of approximately 60 bpm (figure 2).  
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Figure 2: (A) Non stress test before 
treatment revealed fetal bradycardia 
– (B) Non stress test after treatment 
revealed normal fetal heart rate at 120 
beats/minutes. 
Although the patient had 4 previous 
pregnancies which were all complicated 
by hydrops fetalis and intrauterine fetal 
death, testing for SSA/Ro and SSB/La 
antibodies had not been performed. We 
requested these investigations and the 
results were positive. 
The patient started corticosteroid 
therapy (5 mg prednisolone tablets, 
twice daily), and the fetal heart rate and 
arrhythmia improved (figure 2). 
However, the fetus died 2 weeks later, 
possibly due to heart failure.  
Discussion  
This case highlights that early diagnosis 
and management of fetal atrioventricular 
block may be important. A woman with a 
past history of recurrent second-
trimester fetal death may be a candidate 
for the screening of SSA/SSB-antibody. 
There are two types of hydrops fetalis; 
the first is immune hydrops fetalis that 
represents about 12.7% of cases of 
hydrops fetalis and is associated with 
antigen-antibody mediated red blood 
cell hemolysis. The second more 
frequent type of hydrops fetalis is NIH 
which represents about 87.3% of 
cases.6,7 The incidence rate of NIH is 
estimated at 1 in every 3000 
pregnancies.8 The main causes are 
infectious and metabolic diseases, 
chromosomal abnormalities, 
cardiovascular diseases, twin-twin 
transfusion syndrome, anemia and 
idiopathic NIH which has the worst 
prognosis.9,10 
There are different approaches for the 
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detection of fetal arrhythmias: the non-
invasive methods like 
magnetocardiography (FMCG) and fetal 
echocardiography (M-mode, pulsed-
Doppler, tissue-Doppler).11 The invasive 
methods like scalp electrodes attached 
to electrocardiographic recordings are 
seldom employed; it can be used only in 
cases of ruptured membranes. The 
Doppler method is better than the M-
mode for measurement of the fetal 
atrioventricular time intervals.12 
Congenital atrioventricular block can be 
classified according to the etiology of it 
into 3 groups. The first is due to physical 
defects that structurally displace the 
distal conduction system. The second is 
due to the maternal antibodies SSA/Ro 
or SSB/La that yield into an 
inflammatory myocardial response, and 
the last is a block of unclear etiology. It 
is also can be classified depending on 
its severity as first-degree, second-
degree (incomplete) or third-degree 
(complete) block.13 
Isolated, complete atrioventricular block 
with negative SSA/Ro antibody appears 
to have the best long-term 
prognosis.13,14 The cause of this type of 
block remains unclear. Lopes et al. 
described that natural improvement of 
atrioventricular block in utero is possible 
in fetuses whose mothers are 
seronegative for antinuclear antibodies 
throughout pregnancy.15 
Immune atrioventricular block occurs 
due to placental transfer of maternal 
autoantibodies against 
ribonucleoproteins of unknown function. 
SSA/Ro and SSB/La autoantibodies are 
labeled ‘antinuclear antibodies’, but 
~70% of these ribonucleoproteins are 
actually situated in the cytoplasmic 
compartment.16 
First-degree and second-degree 
atrioventricular block have short-lived 
period of reversibility, and early 
diagnosis is critical for treatment, but 
third-degree atrioventricular block is 
permanent.17,18 Complete improvement 
of second-degree block has been 
reported intrauterine.15 Friedman et al. 
documented cure of second-degree 
atrioventricular block in two of six 
fetuses treated with corticosteroids, but 
in spite of this treatment, three of the 
fetuses (50%) progressed to complete 
atrioventricular block (one intrauterine, 
two after delivery).19 The incidence of 
fetal atrioventricular block is about 2% of 
pregnancies in females with SSA/ Ro or 
SSB/La autoantibodies.18 
Serial echocardiography screening is 
not helpful because there has been no 
evidence that this prevented the 
development of atrioventricular block. 
The risk of recurrent atrioventricular 
block when a previous fetus has been 
affected is about 19%.19 The most 
serious complication seen in females 
with positive antibodies is the 
occurrence of repolarization 
abnormalities and this may increase the 
incidence of sudden cardiac arrest 
documented in this group of patients.20  
In a females with SSA/Ro-related fetal 
cardiac complications, follow-up with 
FMCG is highly recommended to 
assess depolarization and repolarization 
anomalies, confirm the degree of block, 
and evaluate myocardial 
hypertrophy21,22 but, this method is still 
not readily accessible to doctors in most 
centers. Actually, it was unavailable in 
our tertiary fetal medicine center. If 
FMCG is not available, such females 
should be followed up with fetal 
echocardiography to measure 
mechanical PR interval and to detect 
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signs of endocardial fibroelastosis, 
tricuspid valve regurgitation, cardiac 
dysfunction, or atrioventricular block.19 
Subsequently repolarization 
abnormalities cannot be documented 
without FECG or FMCG. 
A number of progresses have been 
made in the treatment of fetal 
atrioventricular block. In utero, 
terbutaline has been used to increase 
the heart rate to >55 bpm, or in fetuses 
with signs of hydrops,23 but it has not 
been proven to decrease the incidence 
of fetal or neonatal death. The use of 
steroids for treatment of fetal 
atrioventricular block is debated and at 
present no clear evidence of care is 
available. Due to the non-reversible 
condition of the third-degree 
atrioventricular block, steroids are 
infrequently used to treat it, unless 
myocardial dysfunction or hydrops 
fetalis are also present. Rein and 
colleagues24 suggested that mothers 
who had previously had a fetus with 
atrioventricular block should receive 
steroid treatment in following 
pregnancies if fetal mechanical PR 
intervals ≥150 ms develop.  
Due to the small number of cases in 
each treatment center, no randomized 
control trial is available to properly 
evaluate and compare the efficacy of 
drugs currently used. Available 
information was based on descriptive 
studies. 
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